Results 161 to 170 of about 15,200 (191)

Cytomegalovirus Retinitis Following Daratumumab for Multiple Myeloma: A Case Report and Literature Review. [PDF]

Case Rep Med
Kono A, Bando K, Takahata A, Toyota S.
europepmc   +1 more source

Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma. [PDF]

Blood Cancer J
Sebastian T, Rajeeve S, Farzana T, Firestone R, Jurgens E, Miller K, Costa BA, Lesokhin A, Tan CR, Shah G, Korde N, Landau H, Scordo M, Hassoun H, Maclachlan K, Shah U, Hultcrantz M, Derkach A, Nemirovsky D, Giralt S, Usmani S, Mailankody S, Hashmi H.   +22 more
europepmc   +1 more source

The effects of daratumumab on bone disease in patients with newly diagnosed multiple myeloma: a multi-center retrospective study. [PDF]

BMC Cancer
Li X, Wang H, Li Y, Zhou J, Yang N, Wei X, Cai X, Xiao Z, Du J, Zeng H.   +9 more
europepmc   +1 more source

Effective treatment with daratumumab in post-HSCT refractory immune-mediated cytopenias: a case report and literature review. [PDF]

Front Immunol
Jing XY, Li DJ, Su SN, Dai QK, Sun SW, Huang L, Ai Y, Gao J, Zhu YP, Ni JQ, Lu XX.   +10 more
europepmc   +1 more source

Treatment of transplant-ineligible multiple myeloma. [PDF]

Blood Res
Jung J.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Daratumumab

Reactions Weekly
  +15 more sources

Daratumumab

Reactions Weekly, 2019
  +11 more sources

Daratumumab

Reactions Weekly, 2021
  +5 more sources

Daratumumab

Reactions Weekly, 2022
  +4 more sources

Daratumumab

Reactions Weekly, 2023
openaire   +2 more sources